After AstraZeneca blocked people under the age of 60, the SARS-CoV-2 coronavirus vaccination campaign has undergone a revolutionary change. The government’s decision after the death of the young Camilla Canepa is also related to the risk-benefit ratio in the context of low virus transmission. This is what the EMA data says.
This case The unfortunate 18-year-old from Sestri Levante Camila Canepa, Died of serious Thrombosis After receiving the first dose Vaxefria, Pounce (again) Coronavirus disease vaccine of AstraZeneca In a series of controversies, this prompted the government to permanently suspend the administration of all persons under the age of 60. Italian Medicines Agency (FIFA) Actually recommended a vaccine for some time Adenovirus vector Only in the 60s, like a single dose Johnson & Johnson, Precisely because of the very rare Thromboembolic eventsA few months ago, the emergence of the first cases—especially dangerous sinus venous thrombosis—determined the first temporary discontinuation of the drug and subsequent readjustment. Vaccination campaignHowever, despite AIFA’s recommendations, many regions of Italy continue to vaccinate young people with adenovirus vector vaccines, especially during the hugely successful Open Day. However, the exact cause of the death of the young Ligurian was being checked by experts, and the card on the table was changed, resulting in AstraZeneca (rather than Johnson & Johnson) under the age of 60 being finally blocked.
The decision is followed by statements for and against, the most discussed one (because it was misunderstood) By Dr. Marco Cavaleri, Head of the European Medicines Agency (EMA) Vaccine Working Group.A scientist pointed out Clarify to Reuters The AstraZeneca vaccine “maintains favorable risk-benefit characteristics in all age groups, especially among the elderly over 60 years of age.”It is in the delicate balance between the two Benefits and serious adverse reactions Playing the game of adenovirus vector vaccine, in the context of low circulation Coronavirus SARS-CoV-2 As with the current situation, it may not be significantly beneficial in the younger age group. The British Medicines and Healthcare Products Regulatory Agency (MHRA) has also announced this many times. announcement Regarding epidemiological surveillance (“yellow card”).In addition, as we all know, the youngest will get serious illness Coronavirus disease Compared with more mature age groups, this ratio is much lower, and in cases where the virus spreads very little, assigning certain vaccines based on age may be a successful strategy. Professor Nino Cartabellotta, chairman of the Gimbe Foundation, also said on Twitter: “Due to the low transmission rate of the virus, AstraZeneca’s risks may outweigh the benefits for people under 30.” On the other hand, the EMA has never indicated the age, gender or other restrictions of the AstraZeneca vaccine. It continues to reiterate that “The benefit/risk balance of the AstraZeneca# COVID19 vaccine is positive and still applies to all populations.” Give false information to the case.
in a relationship It was published not long ago that the European Medicines Agency (EMA) emphasized the actual relationship between the two Risks and benefits The vaccine of the British-Swiss community.For example, in the range of 20 to 29 years old, they are 4 odds In 100,000 Avoid hospitalization Compared with SARS-CoV-2 coronavirus infection 1.9 Probability 100,000 people develop one Thrombosis After AstraZeneca vaccination. In the 60-69 age group, 19 out of 100,000 people have the opportunity to avoid hospitalization, and only 1 person will be affected by a blood clot. Therefore, despite the EMA data, even in the youngest group, the obvious advantage of Anglo-Swiss vaccine over more mature groups is obvious.Another Oxford University survey is less acute. According to this survey, people between the ages of 20 and 29 0.8 probability One in 100,000 to avoid intensive care 1.1 Probability Thrombosis occurred after taking Vaxzevria. The probability of avoiding hospitalization for people aged 60-69 is 14.1, and the probability of thromboembolism is 0.2, which highlights the advantages of vaccination for the elderly.